State Street Global Advisors forecasts gold prices may rise to $5,500 per ounce by March 2027, driven by strong structural demand from Asian investors and central banks, and the need for portfolio diversification amid high stock/bond correlation. Although tactical challenges like high yields, a strong U.S. dollar, and expected Federal Reserve rate hikes have pressured gold prices recently, these are outweighed by factors such as record global debt levels, rising government debt, and robust physical gold demand, especially from China. Gold's role as a monetary hedge and diversification asset remains critical as equities and bonds move more closely together. The firm projects a baseline gold price range of $4,750 to $5,500 per ounce over the next 6-9 months, with strong support around $3,750 to $4,000 per ounce.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
